Collaboration and License Agreements - Amgen, Inc (Details)	1 Months Ended	9 Months Ended
	Sep. 30, 2016 USD ($) agreement	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jul. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from the issuance of common stock, net of offering costs		$ 429,265,000	$ 0
Contract liabilities		0		$ 866,000
Amgen | Olpasiran Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of agreements | agreement	2
Upfront payment	$ 35,000,000
Proceeds from the issuance of common stock, net of offering costs	$ 21,500,000
Milestone payments		55,000,000			$ 25,000,000	$ 20,000,000	$ 10,000,000
Contract assets		0
Contract liabilities		0
Amgen | Olpasiran Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional remaining development regulatory and sales milestones payments		$ 485,000,000